

TETRALOGIC PHARMACEUTICALS CORP  
Form S-8 POS  
November 03, 2016

As filed with the Securities and Exchange Commission on November 3, 2016

Registration No. 333-192875

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8**

**REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**TetraLogic Pharmaceuticals Corporation**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
Incorporation or organization)

**P.O. Box 1305  
Paoli, PA 19301**  
(Address, including zip code, of  
Registrant's principal executive  
offices)

**42-1604756**  
(I.R.S. Employer  
Identification No.)

**TETRALOGIC PHARMACEUTICALS CORPORATION  
2004 EQUITY INCENTIVE PLAN**

**TETRALOGIC PHARMACEUTICALS CORPORATION  
AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN**

Edgar Filing: TETRALOGIC PHARMACEUTICALS CORP - Form S-8 POS

(Full title of the plans)

**J. Kevin Buchi**  
**President and Chief Executive Officer**  
**P.O. Box 1305**  
**Paoli, PA 19301**  
**(610) 889-9900**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*With Copies to:*

**Jeffrey P. Libson, Esq.**  
**Pepper Hamilton LLP**  
**400 Berwyn Park**  
**899 Cassatt Road**  
**Berwyn, PA 19312-1183**  
**Tel: (610) 640-7800**  
**Fax: (610) 640-7835**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

**(Do not check if a smaller reporting company)**

---

**DEREGISTRATION OF COMMON STOCK**

This Post-Effective Amendment No. 1 (this Post-Effective Amendment) relates to the Registration Statement of TetraLogic Pharmaceuticals Corporation (TetraLogic) on Form S-8 (File No. 333-192875) filed with the Securities and Exchange Commission (the SEC) on December 16, 2013 (the Registration Statement), pursuant to which TetraLogic registered the offer and sale from time to time of its shares of common stock issuable pursuant to its 2004 Equity Incentive Plan and Amended and Restated 2013 Equity Incentive Plan referred to therein (the Common Stock).

TetraLogic is filing this Post-Effective Amendment to terminate the effectiveness of the Registration Statement and, in accordance with an undertaking made by TetraLogic pursuant to the terms of the Registration Statement, remove from registration any and all shares of Common Stock registered but unsold under the Registration Statement as of the date hereof. As a result of this deregistration, no Securities or other

securities remain registered for offer and sale pursuant to the Registration Statement.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in Paoli, Pennsylvania on November 3, 2016.

TetraLogic Pharmaceuticals Corporation

By:	/s/ J. Kevin Buchi
Name:	J. Kevin Buchi
Title:	President and Chief Executive Officer

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment.

---